Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a proprietary droplet-based microfluidic screening workstation.


Biotechnology

Veraxa Biotech

Christoph Antz

Yasemin Doeger

Heinz Schwer Ph.D.

Marian Weiss

Anna Pryszlak

Torsten Bürgermeister

Edward A. Lemke

Steffen Runz

Paul F. Sauter

Christine Köhler

Michael Ruppert

Christoph A. Merten

Lars Hufnagel

The Leadership Team at Veraxa Biotech drives strategic direction and operational excellence in the development of their innovative antibody screening platform. Comprising seasoned experts in biotechnology, finance, and technology, this team collaborates to enhance research and development initiatives, ensure effective resource allocation, and propel the company's mission of maximizing the potential of immune repertoires through groundbreaking biotechnological advancements.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at Veraxa Biotech

Research and Development